OTC: ACXIF 21.95%
Underperform Recommendation Issued On ACXIF By RBC Capital
NASDAQ: NGNE 31.15%
Neurogene Shares Rally on FDA Breakthrough Therapy Designation for Rett Syndrome Therapy
NASDAQ: BYND 32.83%
Expected US Company Earnings on Wednesday, February 25th, 2026
NYSE: BATL 21.08%
Halftime Market Summary: Stocks to Watch before Super Bowl Weekend
NYSE: KORE 77.39%
KORE Reports Third Quarter 2025 Results
NASDAQ: MGN 34.5%
Megan Holdings Limited Announces Closing of $8.3 Million Follow-on Public Offering
NASDAQ: ACXIF 31.15%
NASDAQ: BYND 31.15%
NASDAQ: BATL 31.15%
NASDAQ: KORE 31.15%
